Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
3/1/1994
1.
Phase Ib/IIa Study of Murine Anti-Idiotypic MOAB BEC2 with Alum Adjuvant in Patients with Advanced Melanoma (Summary Last Modified 03/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
MSKCC-93103A1
NCI-V93-0338
Last Modified:
1/1/2000
 
First Published:
1/1/2000
2.
Phase I/II Study of Human Anti-Idiotypic Monoclonal Antibody Vaccine (4B5) in Patients with Stage III or IV Melanoma at High Risk for Recurrence Following Surgical Resection
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
Over 18
NCI
UAB-9746
UAB-F980729009, NCI-G99-1644, NCT00004184
Last Modified:
2/7/2005
 
First Published:
1/1/2001
3.
Phase I/II Study of Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine and ONYCR1, ONYCR2, and ONYCR3 Allogeneic Adenocarcinoma Cell-Based Vaccines in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Colon or Rectum
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
ONYVAX-SGCRO01
NCI-V00-1599, NCT00007826
Last Modified:
1/1/2000
4.
Phase II Randomized Study Comparing Immunologic Responses of Stage II and III Colorectal Cancer Patients on Adjuvant Therapy Treated with 3H1 Anti-Idiotype Monoclonal Antibody Mixed with Sargramostim Versus 3H1 Anti-Idiotype Monoclonal Antibody Alum Precipitate Mixed with Sargramostim (Summary Last Modified 01/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
UKMC-95GI24CB
NCI-H97-1184
Last Modified:
6/21/2006
 
First Published:
3/1/2002
5.
Phase II Randomized Adjuvant Study of Vaccination With Tyrosinase, gp100, and MART-1 Peptides Emulsified With Montanide ISA-51 With Interleukin-12 and Either Alum Adjuvant or Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
LAC-USC-10M011
LAC-USC-IRB-013030, NCI-5506, NCT00031733, 5506
Last Modified:
1/1/2000
6.
Phase I Pilot Study of Immunotherapy with Rat Monoclonal Anti-Idiotypic Antibody BR3E4 (Ab2) with Alum as Adjuvant for Surgically Incurable Colorectal Cancer (Summary Last Modified 01/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
over 18
NCI
JMC-9309057
NCI-H96-0001
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute